WO2000009506A1 - Derives de 1h-imidazopyridine - Google Patents

Derives de 1h-imidazopyridine Download PDF

Info

Publication number
WO2000009506A1
WO2000009506A1 PCT/JP1999/004381 JP9904381W WO0009506A1 WO 2000009506 A1 WO2000009506 A1 WO 2000009506A1 JP 9904381 W JP9904381 W JP 9904381W WO 0009506 A1 WO0009506 A1 WO 0009506A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
elemental analysis
experimental
ethyl
solvent
Prior art date
Application number
PCT/JP1999/004381
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Hideo Kato
Jun Sakaguchi
Makoto Aoyama
Tomoyuki Izumi
Ken-Ichi Kato
Original Assignee
Hokuriku Seiyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ509939A priority Critical patent/NZ509939A/xx
Priority to HU0103406A priority patent/HUP0103406A3/hu
Priority to EA200100230A priority patent/EA200100230A1/ru
Priority to HK02103246.4A priority patent/HK1042295A1/zh
Priority to HR20010144A priority patent/HRP20010144A2/hr
Priority to SK194-2001A priority patent/SK1942001A3/sk
Priority to BR9914306-2A priority patent/BR9914306A/pt
Priority to CA002339562A priority patent/CA2339562A1/en
Priority to EP99937053A priority patent/EP1104764A4/en
Priority to PL99346155A priority patent/PL346155A1/xx
Application filed by Hokuriku Seiyaku Co., Ltd. filed Critical Hokuriku Seiyaku Co., Ltd.
Priority to US09/744,959 priority patent/US6518265B1/en
Priority to AU51974/99A priority patent/AU744388B2/en
Priority to IL14122699A priority patent/IL141226A0/xx
Publication of WO2000009506A1 publication Critical patent/WO2000009506A1/ja
Priority to NO20010676A priority patent/NO20010676L/no
Priority to BG105271A priority patent/BG105271A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention has a potent inhibitory effect on the production of tumor necrosis factor (TNF) and interleukin-1 (IL-1) and is a chronic inflammatory disease in humans or animals (eg, rheumatoid arthritis, osteoarthritis, etc.) , Allergic rhinitis, atopic dermatitis, contact dermatitis, asthma, sepsis, septic shock, various autoimmune diseases [autoimmune blood disease (eg, hemolytic anemia, aplastic anemia, idiopathic thrombocytopenia) Disease), autoimmune bowel disease (eg, ulcerative colitis, Crohn's disease), autoimmune keratitis (eg, keratoconjunctivitis sicca, spring conjunctivitis, etc.), endocrine ocular disorders, Graves' disease, sarcoidosis, Multiple sclerosis, systemic lupus erythematosus, polychondritis, scleroderma, active chronic he
  • imiquimod has several cytokine-inducing effects, such as interferon (IFN), TNF, and IL-11, as reported in the Journal of Interferon Research. ), Vol. 14, p. 81 (1994), but 1H-imidazopyridine derivatives and 1H having an inhibitory effect on the production of TNF and IL-1 which are completely inconsistent with these prior arts. —I Midazoquinoline derivatives have never been known before. Disclosure of the invention
  • An object of the present invention is to provide a novel compound which has an excellent inhibitory effect on the production of cytokines such as TNFIIL-l and is useful as a medicament.
  • the present inventors have conducted intensive studies to solve such problems, and as a result, have found a novel 1 H-imidazopyridine derivative having an excellent TNF and IL-11 production inhibitory action, and completed the present invention.
  • R 1 represents a hydrogen atom, a hydroxyl group, an alkyl group which may have one or more substituents, a cycloalkyl group which may have a substituent
  • R 2 may have a hydrogen atom, an alkyl group, a halogen atom, a hydroxyl group, and one or two substituents
  • a ⁇ represents one or more alkyl groups or alkoxy groups
  • R 3 represents a saturated nitrogen-containing heterocyclic group which may have a substituent
  • m represents an integer of 0 to 3.
  • R 3 represents an unsubstituted piperidin
  • the present invention relates to a novel 1H-imidazopyridine derivative represented by or a salt thereof.
  • R 4 is a hydrogen atom, an alkyl group, a benzyl group, a triphenylmethyl group, an alkanoyl group which may have a substituent, an alkoxycarbonyl A benzyloxycarbonyl group, a thiocarbamoyl group which may have a substituent, an alkanesulfonyl group, a benzenesulfonyl group or an amidino group which may have a substituent, and Y is a methylene group, an oxygen atom , A sulfur atom, a nitrogen atom, a group or a bond represented by NH, and n represents an integer of 0 to 2.)
  • a medicament comprising, as an active ingredient, the compound represented by the general formulas (I) and (II) or a pharmaceutically acceptable salt thereof.
  • This medicine is used for the treatment of chronic inflammatory diseases (eg, rheumatoid arthritis, osteoarthritis, etc.) in mammals including humans, allergic rhinitis, atopic dermatitis, contact dermatitis, asthma, Sepsis, septic shock, various autoimmune diseases [autoimmune blood diseases (eg, hemolytic anemia, aplastic anemia, idiopathic thrombocytopenia, etc.), autoimmune bowel diseases (eg, ulcerative colitis, Crohn's disease, etc.), autoimmune keratitis (eg, keratoconjunctivitis sicca, spring conjunctivitis, etc.), endocrine ocular disorders, Graves' disease, sarcoidosis, multiple sclerosis, systemic lupus erythematosus, polychondriti
  • cytokine-mediated diseases such as TNF or IL-1.
  • a tumor necrosis factor (TNF) production inhibitor or an inulin leukin-11 comprising as an active ingredient the compound represented by the general formulas (I) and (II) or a pharmacologically acceptable salt thereof.
  • TNF tumor necrosis factor
  • IL-1 production inhibitors are provided by the present invention.
  • the compound represented by the general formula (II) is a compound represented by the general formula (I) it is characterized by having a specific particular which may have a substituent saturated nitrogen-containing heterocyclic group as R 3.
  • the scope of the present invention is not limited to the compound represented by the general formula (II), and any of the compounds having a saturated nitrogen-containing heterocyclic group which may have a substituent as R 3 includes: It goes without saying that it is included in the scope of the present invention.
  • R " the alkyl group represented by R 2 and R 4, for example, a methyl group, Echiru group, .eta. propyl group, an isopropyl group, n- Examples include butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
  • Examples of the cycloalkyl group represented by R 1 include a cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group.
  • Examples of the aryl group represented by R 1 include: Phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyrazinyl, 2- Furyl, 3-furyl, 2-phenyl, 3-phenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl , 1-Bilazolyl group, 3-Bilazolyl group, 4-Pyrazolyl group, 5-Pyrazolyl group, 2-Oxazolyl group, 4-Oxazolyl
  • Examples of the halogen atom represented by R 2 include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and an amino group which may have one or two substituents represented by R 2 Examples thereof include an amino group, a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group, a cyclopropylamino group, a cyclobutylamino group, a cyclopentylamino group, a cyclohexylamino group, and a dimethylamino group.
  • a cyclic amino group represented by R 2 includes, for example, a benzyl group, a acetylamino group, a phenylamino group, a pyridylamino group, a 4-pyridylmethylamino group, a benzylamino group, a p-methoxybenzylamino group, and a dibenzylamino group.
  • examples of the homo or hetero ring represented by the ring A include, for example, a benzene ring, a cyclopentene ring, a cyclohexene ring, a cycloheptene ring, a cyclooctene ring, and a cycloheptadiene.
  • Is for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isoptyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n -Hexyl group and the like
  • the alkoxy group which may be substituted includes, for example, methoxy group, ethoxy group, n-propoxy group, isopropoxy group n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, ⁇ -pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, etc.
  • Good halogen atoms include, for example, fluorine, chlorine, bromine and iodine. The number and type of these substituents are not particularly limited, and when two or more substituents are present, they may be the same or different.
  • the saturated nitrogen-containing heterocyclic group represented by R 3 has at least one nitrogen atom as a ring-constituting atom, and further has an oxygen atom or a sulfur atom as a ring-constituting atom.
  • -Piperidyl group 4-piperidyl group, 1-piperazinyl A 2-piperazinyl group, a 3-pyrrolidinyl group, a 2-azetidinyl group, a 3-azetidinyl group, a 2-morpholinyl group, and a 2-thiomorpholinyl group.
  • examples of the alkanol group which may have a substituent represented by R 4 include, for example, formyl group, acetyl group, propionyl group, n-butyryl group, isoptyryl group, valeryl group, isovaleryl Group, bivaloyl group, fluoroacetyl group, difluoroacetyl group, trifluoroacetyl group, chloroacetyl group, dichloroacetyl group, trichloroacetyl group, and the like.
  • the alkoxycarbonyl group represented by R 4 includes For example, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, n-pentylo Xycarbonyl group, n-hexyloxycarbonyl And thiocarbamoyl which may have a substituent represented by R 4 include, for example, thiocarbamoyl, methylthiocarbamoyl, ethylthiocarbamoyl, n-propylthiocarbamoyl, isopropylthio Alkamosulfonyl group, n-butylthio alkamoyl group, isobutylthio sorbamoyl group, sec-butylthio sorbamoyl group, tert-but
  • alkane sulfonyl group represented by R 4 examples include methanesulfonyl Ki, Eta And sulfonyl group, n-propanesulfonyl group, n-butanesulfonyl group and the like.
  • the substitution / bonding site of the “aryl group”, the “homologous or heterocyclic group” and the “saturated nitrogen-containing heterocyclic group” is, as partially exemplified above, particularly the substitution / bonding site.
  • the term is used as a concept including a group which may be substituted / bonded at any position in the ring constituent as long as it is an element which can be substituted / bonded.
  • any functional group may be used as long as it is a group capable of substituting these groups.
  • the number and types of the substituents are not particularly limited. When two or more substituents are present, they may be the same or different.
  • halogen atoms such as a fluorine atom, a chlorine atom, and a bromine atom, a hydroxyl group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, Alkyl groups such as n-pentyl group, isopentyl group, neopentyl group, n-hexyl group, aryl groups such as trifluoromethyl group, phenyl group, naphthyl group, pyridyl group, methoxy group, ethoxy group , N-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, alkoxy group such as tert-butoxy group, aryloxy group such as phenoxy group, amino group,
  • Alkylthiol group Lumbamoyl group, amidino group, methylthio group, etc.
  • alkylthio group methanesulfinyl group Alkanesulfonyl, methanesulfonyl, benzenesulfonyl, n-propanesulfonyl, n-butanesulfonyl, and other alkanesulfonyl, p-toluenesulfonyl, p-methoxybenzenesulfonyl, p-fluoro Arylsulfonyl groups such as benzenesulfonyl group, aralkyl groups such as benzyl group, naphthyl group, pyridylmethyl group, furfuryl group, triphenylmethyl group, nitro group, cyano group, sulfamoyl group, oxo group, hydroxy group Imino group, methoxymino And ethoxyimino groups, alkoxyimino groups such as n-propoxyimino group, and
  • the compounds represented by the above general formulas (I) and (II) of the present invention can be converted into a salt, preferably a pharmacologically acceptable salt, or a base can be liberated from the produced salt, if desired. You can also.
  • the salts of the compounds of the present invention represented by the general formulas (I) and (II), preferably pharmaceutically acceptable salts, include acid addition salts, for example, hydrochloric acid, hydrobromic acid, iodine Mineral acid salts such as hydrofluoric acid, nitric acid, sulfuric acid and phosphoric acid, or acetic acid, propionic acid, butyric acid, formic acid, valeric acid, maleic acid, fumaric acid, citric acid, oxalic acid, malic acid, Succinic acid, lactic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mandelic acid, 10-camphorsulfonic acid, tartaric acid, stearic acid, gluconic acid, nicotinic acid, trifluoroacetic acid, benzoic acid, etc.
  • Organic acid salts for example, hydrochloric acid,
  • compounds having an asymmetric carbon may have optical isomers, and the present invention also includes these optically active isomers and mixtures thereof. Included.
  • the compound represented by the above general formulas (I) and (II) or a salt thereof according to the present invention can exist in any crystal form depending on the production conditions, and exist as an arbitrary hydrate or solvate. However, these crystal forms, hydrates or solvates, and mixtures thereof are also included in the scope of the present invention.
  • Preferred compounds of the present invention include, for example, the following compounds and salts thereof, but the present invention is not limited to these examples.
  • the novel 1 H-imidazopyridin derivative represented by the general formula (I) or ( ⁇ ) of the present invention can be produced by various methods, but the method of producing the compound of the present invention is not limited to these methods. It is not done. In the following production methods, the compound represented by the general formula (I) will be specifically described. However, it is noted that the compound represented by the general formula ( ⁇ ) is included in these production methods. It is obvious.
  • the following synthesis method is used according to the method disclosed in JP-A-3-206078 or Tetrahedron, Vol. 51, p. 5813 (1995). be able to.
  • R 5 represents a hydroxyl group or an alkyl group
  • R 6 represents a chlorine atom or an alkyl group
  • R represents the same meaning as R 1 (excluding the hydroxyl group)
  • the compound represented by the general formula (III) is treated with a nitric acid such as concentrated nitric acid or fuming nitric acid in the presence or absence of acetic acid or sulfuric acid at 0 ° C to 200 ° C.
  • a nitric acid such as concentrated nitric acid or fuming nitric acid
  • acetic acid or sulfuric acid at 0 ° C to 200 ° C.
  • step 2 the compound of the general formula (IV) is treated with a suitable chlorinating agent, for example, oxyphosphorus chloride, thionyl chloride, phosgene, oxalyl chloride, phosphorus pentachloride, etc., in the presence or absence of a solvent such as toluene.
  • a suitable chlorinating agent for example, oxyphosphorus chloride, thionyl chloride, phosgene, oxalyl chloride, phosphorus pentachloride, etc.
  • step 3 the amine represented by the general formula (VI) and the compound represented by the general formula (V) are mixed with a base such as triethylamine or potassium carbonate in a solvent such as N, N-dimethylformamide or toluene.
  • a base such as triethylamine or potassium carbonate
  • a solvent such as N, N-dimethylformamide or toluene.
  • the compound of the general formula (VII) can be obtained by reacting at a temperature of from 11 ° C to the reflux temperature of the solvent in the absence or in the absence.
  • Step 4 the compound of the general formula (VII) is reduced by a suitable method such as platinum, A catalytic reduction method using a metal catalyst such as nickel nickel or palladium carbon, a reduction method using nickel chloride and sodium borohydride, a reduction method using iron powder and hydrochloric acid, etc.
  • a suitable method such as platinum, A catalytic reduction method using a metal catalyst such as nickel nickel or palladium carbon, a reduction method using nickel chloride and sodium borohydride, a reduction method using iron powder and hydrochloric acid, etc.
  • the compound of (VIII) can be obtained.
  • the reduction reaction can be carried out in a solvent such as water, methanol, ethanol, tetrahydrofuran or a mixed solvent thereof at a temperature between 0 and the reflux temperature of the solvent.
  • a solvent such as water, methanol, ethanol, tetrahydrofuran or a mixed solvent thereof at a temperature between 0 and the reflux temperature of the solvent.
  • Step 5 the compound of the general formula (VIII) is combined with the following general formula (XI), (XII) or (XIII)
  • R represents a lower alkyl group
  • X represents a halogen atom
  • ⁇ Has the same meaning as!? ⁇ (Excluding the hydroxyl group.)
  • Step 6 a compound of the general formula (VIII) and a compound of the following general formula (XIV)
  • Step 7 the compound of the above general formula (VIII) and the following general formula (XV) R '' COOH (XV)
  • the compound of formula (1) is reacted at 0 ° C to 200 ° C in the presence or absence of an acid catalyst such as hydrochloric acid or sulfuric acid, in the presence or absence of a solvent such as N, N-dimethylformamide or toluene.
  • an acid catalyst such as hydrochloric acid or sulfuric acid
  • a solvent such as N, N-dimethylformamide or toluene.
  • the compound of the general formula (X) may be treated, if necessary, with a protecting group such as an alkanoyl group, which binds a nitrogen atom which is not bonded to the adjacent (CH 2 ) m group of the saturated nitrogen-containing heterocyclic group represented by R 3.
  • a suitable chlorinating agent for example, phosphorus oxychloride, thionyl chloride, phosgene, oxalyl chloride, phosphorus pentachloride, etc. in the presence or absence of a solvent such as toluene at 0 °.
  • the compound is reacted at a temperature between C and 200 ° C., and if necessary, deprotected by a conventional method to obtain a compound of the general formula (IX) in which R 6 is a chlorine atom.
  • the compound of the general formula (VIII) is combined with triphosgene in the presence of a base such as triethylamine or potassium carbonate in the presence of 1,2-dichloromethane, 1,4-dioxane, tetrahydrofuran,
  • a base such as triethylamine or potassium carbonate
  • 1,2-dichloromethane, 1,4-dioxane, tetrahydrofuran By reacting in a solvent such as N, N-dimethylformamide or toluene between 0 ° C and the reflux temperature of the solvent, the compound represented by the general formula (XVI)
  • aryl substituted with a methylthio group as R 1 ′ is used.
  • the compound of the general formula (IX) having a phenyl group as a substituent is optionally substituted with a nitrogen atom which is not bonded to the adjacent (CH 2 ) m group of the saturated nitrogen-containing heterocyclic group represented by R 3 by a conventional method.
  • an appropriate oxidation reaction is carried out, and if necessary, deprotection is carried out by a conventional method.
  • Z represents an aromatic ring
  • a represents an integer of 1 or 2
  • R 3 , R 6 , m, and A ⁇ have the same meanings as described above.
  • the oxidation reaction can be performed by various methods according to the target substance. That is, when a represents an integer of 1, for example, using an oxidizing agent such as chromic acid, hydrogen peroxide, m-chloroperbenzoic acid, sodium periodate, or potassium periodate, In the case of representing an integer, for example, using oxidizing agents such as chromic acid, hydrogen peroxide, m-chloroperbenzoic acid, osmium tetroxide, ruthenium tetroxide, tetrahydrofuran, 1,4-dioxane It can be produced by reacting in 0, 1,2-dichloroethane, methanol, acetone or water, or a mixed solvent thereof between 0 ° C and the reflux temperature of the solvent.
  • an oxidizing agent such as chromic acid, hydrogen peroxide, m-chloroperbenzoic acid, sodium periodate, or potassium periodate
  • oxidizing agents such as chromic acid, hydrogen peroxide
  • a compound of the general formula (I) in which R 2 is a chlorine atom is prepared by using water and an appropriate acid or base in a solvent at 0 ° C. to the reflux temperature of the solvent.
  • Suitable acids include, for example, organic acids such as formic acid, acetic acid, and trifluoroacetic acid, and mineral acids such as hydrochloric acid, sulfuric acid, and hydrobromic acid.
  • Suitable bases include, for example, sodium hydroxide and the like. Al force of metal or magnesium or calcium Examples include hydroxides, carbonates or bicarbonates of lithium earth metals.
  • the solvent examples include alcohols such as methanol, ethanol, and n-propanol, N, N-dimethylformamide, , 4-dioxane, tetrahydrofuran and the like, or their hydrated solvents.
  • the compound of the general formula (I) in which R 2 is a chlorine atom and R 1 is R 11 , or the general formula (I) in which R 2 is a hydroxyl group and R 1 is R ′′ A compound obtained by reacting the compound of formula (1) with trifluoromethanesulfonic anhydride, methyl sulfonyl chloride or p-toluene sulfonyl chloride, and a metal halide (eg, lithium fluoride, sodium fluoride, lithium fluoride) , Potassium bromide, sodium bromide, potassium iodide, sodium iodide, etc.) in an aprotic polar solvent such as dimethyl sulfoxide, N, N-dimethylformamide or acetonitrile.
  • a metal halide eg, lithium fluoride, sodium fluoride, lithium fluoride
  • aprotic polar solvent such as dimethyl sulfoxide, N, N-dimethylform
  • R 2 is a fluorine atom, bromine atom or iodine atom, 1 1 to give a compound of 1 1 'Dearu over general formula (I).
  • R 3 are adjacent (CH 2) on the nitrogen atom not bound to the m group, Arukanoiru group, an alkoxycarbonyl group, Baie Njiru group, Torifuruo
  • a compound that is a saturated nitrogen-containing heterocyclic group having a protective group such as a methyl group is deprotected using an acid or alkali or a catalytic reduction reaction using a metal catalyst, depending on the type of the nitrogen-protecting group.
  • a compound can be obtained in which R 3 is a saturated nitrogen-containing heterocyclic group in which the nitrogen atom not bonded to the adjacent (CH 2 ) m group is deprotected.
  • the deprotection reaction using an acid or an alkali can be carried out by using a suitable acid or base and reacting in a solvent in the presence or absence of a cationic benzene such as anisol or thioanisole.
  • a cationic benzene such as anisol or thioanisole.
  • the solvent used include ethyl acetate, methylene chloride, 1,2-dichloroethane, 1,4-dioxane, methanol, ethanol, n-propanol, N, N-dimethylformamide, and tetrahydrochloride.
  • examples thereof include drofuran or water, or a mixed solvent thereof.
  • Examples of the acid used include hydrochloric acid, ethyl acetate solution of hydrogen chloride, ethanol solution of hydrogen chloride, sulfuric acid, hydrobromic acid, trifluoroacetic acid, methanesulfonic acid, and
  • Examples of the base include toluenesulfonic acid, formic acid, and acetic acid.
  • Examples of the base include hydroxides, carbonates, and hydrogencarbonates of alkaline metals such as sodium hydroxide and alkaline earth metals such as magnesium and calcium.
  • the reaction can be carried out at a temperature between 0 ° C. and the reflux temperature of the solvent.
  • the catalytic reduction reaction is carried out using an appropriate metal catalyst such as platinum, palladium carbon, Raney nickel, Pearlman's reagent, etc.
  • reaction in water, alcohols such as methanol, ethanol, n-propanol, acetic acid, or a mixed solvent thereof.
  • the reaction can be carried out in the presence or absence of an acid such as hydrochloric acid between room temperature and the reflux temperature of the solvent at a pressure from normal pressure to 200 kg / cm 2 .
  • a compound of the general formula (I) wherein R 2 is a chlorine atom and a phenol derivative which may have a substituent are synthesized by using sodium hydroxide, potassium hydroxide or the like.
  • R 2 is substituted.
  • the compound of the general formula (I) in which R 2 is a chlorine atom is converted to an amine derivative or a substituent having one or two substituents.
  • the compound of the general formula (I) in which R 2 obtained by the ninth synthesis method is a benzylamino group, a dibenzylamino group or a p-methoxybenzylamino group, by catalytic reduction using a suitable metal catalyst, or, R 2 is p - a compound which is a main butoxy benzyl ⁇ amino group, by a deprotection reaction child with an acid, in which it R 2 is amino groups
  • R 2 is p - a compound which is a main butoxy benzyl ⁇ amino group
  • the catalytic reduction reaction is carried out at room temperature to the reflux temperature of the solvent in an alcohol such as methanol or ethanol or water, or a mixed solvent thereof, under normal pressure or under pressure, under conditions of hydrochloric acid, acetic acid, formic acid, etc.
  • an alcohol such as methanol or ethanol or water, or a mixed solvent thereof
  • hydrochloric acid such as acetic acid, formic acid, etc.
  • a metal catalyst such as palladium carbon, Pearlman's reagent
  • the deprotection reaction using an acid is carried out in a solvent such as an alcohol such as methanol or ethanol, a solvent such as methylene chloride, 1,2-dichloroethane, 1,4-dioxane, tetrahydrofuran, toluene, N, N-dimethylformamide.
  • a solvent such as an alcohol such as methanol or ethanol
  • a solvent such as methylene chloride, 1,2-dichloroethane, 1,4-dioxane, tetrahydrofuran, toluene, N, N-dimethylformamide.
  • an acid such as hydrochloric acid, sulfuric acid, trifluoroacetic acid, or trifluoromethanesulfonic acid in the presence or absence of a cation force venger such as anisol or thioanisole, and the reflux temperature of the solvent from 0 ° C Can be done between
  • a compound in which R 3 is a saturated nitrogen-containing heterocyclic group having an ethylenedioxy group as a substituent in the general formula (I) is prepared by converting hydrochloric acid, hydrogen chloride, ethyl acetate solution, chloride Hydrogen ethanol solution, sulfuric acid, hydrobromic acid, trifluoroacetic acid, P-toluenesulfonic acid, formic acid, acetic acid, and other acids are used to prepare ethyl acetate, methylene chloride, 1,4-dioxane, tetrahydrofuran, methanol, Ethanol, n- By reacting at 0 ° C to 200 ° C in the presence or absence of a solvent such as propanol, N, N-dimethylformamide or a water-containing solvent thereof, R in the general formula (I) Compound 3 is a saturated nitrogen-containing heterocyclic group having an oxo group as
  • R 7 represents a hydrogen atom or an alkyl group.
  • the compound of formula (I) is reacted with methanol, ethanol, and n-amine in the presence or absence of bases such as triethylamine, diisopropylethylamine, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, and sodium acetate.
  • bases such as triethylamine, diisopropylethylamine, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, and sodium acetate.
  • a compound of the general formula (I) in which R 2 is a chlorine atom is converted to a compound such as platinum, palladium carbon or the like in the presence or absence of an acid such as hydrochloric acid or acetic acid.
  • a compound of the general formula (I) wherein R 2 is a hydrogen atom by catalytic reduction in an alcoholic solvent such as methanol or ethanol or an aqueous solvent thereof at room temperature to the reflux temperature of the solvent with a metal catalyst under atmospheric pressure. can be obtained.
  • R 3 is a saturated nitrogen-containing heterocyclic group having no protecting group at a nitrogen atom which is not bonded to an adjacent (CH 2 ) m group.
  • R 3 is a saturated nitrogen-containing heterocyclic group having an appropriate substituent at a nitrogen atom not bonded to the adjacent (CH 2 ) m group.
  • the reaction was N, N-dimethylformamide, methylene chloride, tetrahydrofuran, Triethylamine, potassium carbonate, etc. in the presence or absence of solvents such as toluene, pyridine, nitrobenzene, 1,2-dichloroethane, 1,4-dioxane, methanol, ethanol, n-propanol or water, or a mixed solvent thereof
  • solvents such as toluene, pyridine, nitrobenzene, 1,2-dichloroethane, 1,4-dioxane, methanol, ethanol, n-propanol or water, or a mixed solvent thereof
  • the reaction can be carried out at 0 ° C to 200 ° C in the presence or absence of a base.
  • Suitable reagents include, for example, alkyl halides, triphenylmethyl chloride, benzyl chloride, benzhydryl chloride, formic acid 'formalin mixture, acetyl chloride, acetic anhydride, trifluoroacetic anhydride, benzoyl chloride, benzyl carbonate, Ethyl chlorocarbonate, ditert-butyl dicarbonate, sodium cyanate, alkyl isocyanate, sodium thiocyanate, alkyl thiocyanate, 1H-vinylazo 1-carboxamidine, methanesulfonyl chloride, p-methyl chloride Examples include toluenesulfonyl, P-fluorobenzenesulfonyl chloride, urethane, alkyl urethane, thiourethane, and alkylthiourethane.
  • R 3 is a saturated nitrogen-containing heterocyclic compound having an alkyl group or a benzyl group as a substituent on a nitrogen atom which is not bonded to an adjacent (CH 2 ) m group.
  • a compound that is a cyclic group and an alkyl chlorocarbonate or benzyl chlorocarbonate are mixed in the presence or absence of a solvent such as methylene chloride or toluene, in the presence or absence of a base such as triethylamine or carbonated lime.
  • R 3 in general formula (I) is not bonded to the adjacent (CH 2 ) m group.
  • a compound which is a saturated nitrogen-containing heterocyclic group having a carbonyl group as a substituent can be obtained.
  • the compounds represented by the general formulas (II0 to (VIII)) used as starting materials and intermediates in the production method of the compound of the present invention are partially known compounds, for example, Journal of Medicinal Chemistry, Vol. 18, page 726. Vol. 33, p. 1880 (1990); Vol. 40, p. 1779 (1997), International Patent Publication No. 97/20820, European Patent Publication No. 223124 (1987). Etc., and can be produced according to the methods described therein.In addition, for some novel compounds, the production methods are described as reference examples.
  • compositions containing the novel 1 H-imidazopyridine derivative represented by the above general formula (I) or (II) or a salt thereof as an active ingredient produced in this manner are usually capsules, tablets, and fine granules.
  • Oral preparations such as granules, powders, powders, syrups and dry syrups, or parenteral injections such as injections, suppositories, eye drops, eye ointments, ear drops, nasal drops, dermatological agents, inhalants, etc. It is administered as a formulation.
  • These preparations can be manufactured by a conventional method by adding pharmacologically and pharmaceutically acceptable additives.
  • excipients lactose, D-mannitol, corn starch, crystalline cellulose, etc.
  • disintegrants carboxymethylcellulose, etc.
  • binders Hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, etc.
  • lubricants magnesium stearate, talc, etc.
  • coating agents hydroxypropylmethylcellulose, sucrose, titanium oxide, etc.
  • base materials polyethylene
  • pharmaceutical ingredients such as glycols, hard fats, etc.
  • aqueous or solubilizers or solubilizers that can constitute a dissolvable dosage form when used (distilled water for injection).
  • Physiological saline, propylene glycol, etc. pH regulator (inorganic Is an organic acid or base), isotonic agents (salts, glucose, glycerin, etc.), stabilizers, etc.
  • ophthalmic ointments and dermatological agents are ointments, creams, Appropriate formulation components (white petrolatum, macrogol, glycerin, cotton cloth, etc.) are used as patches.
  • the dose of this compound to treated patients depends on the patient's symptoms, but is usually about 0.1 to 100 mg for oral administration and 0.0 for parenteral administration as a daily dose for adults. About 1 to 500 mg can be administered once or several times a day. However, it is desirable to appropriately increase or decrease the dose according to the purpose of treatment or prevention, the site and type of the disease, the age and symptoms of the patient.
  • Methanesulfonic acid (N-triphenylmethyl-4-piperidyl) methyl Under ice-cooling, 84.0 g of N-triphenylmethyl-4-piperidinemethanol and 36.2 ml of triethylamine were added to a 420 ml solution of anhydrous tetrahydrofuran in 420 ml of anhydrous methanesulfonyl chloride. 3 ml was added dropwise, and the mixture was stirred at room temperature for 5.5 hours. Water was added to the reaction mixture and extracted with getyl ether.
  • the extract was washed successively with water and saturated saline, and then dehydrated.
  • the solvent was distilled off, a mixed solution of isopropanol and methanol was added, and the precipitated crystals were collected by filtration and washed with methanol. 90.4 g of colorless crystals were obtained. Recrystallization from a mixture of methylene chloride and methanol gave colorless prisms having a melting point of 129.5 to 134 ° C.
  • Recrystallization solvent methanol-rugetyl ether
  • the solid obtained by evaporating the solvent was washed with n-heptane to obtain 54.4 g of colorless crystals.
  • 22.9 g of sodium azide and 220 ml of ⁇ , ⁇ -dimethylformamide were added to the obtained crystals, and the mixture was stirred at 70 C for 4 hours.
  • insolubles were removed by filtration, and the filtrate was concentrated, and water was added to the obtained residue, followed by extraction with ethyl acetate.
  • the extract was washed successively with water and saturated saline and then dehydrated, and the solvent was distilled off to obtain 43.2 g of a yellow liquid.
  • N-triphenylmethyl-4-piperidineacetic acid 23.6 g, potassium carbonate 16.
  • a suspension of 9 g and 5.0 ml of anhydrous N, N-dimethylformamide in 5.0 ml of suspension was stirred at 90 ° C for 5 hours. After cooling, water and ethyl acetate were added to the reaction mixture, and the precipitated crystals were collected by filtration and washed with water to obtain 20.6 g of colorless crystals. Recrystallization from a mixed solution of methanol and tetrahydrofuran gave colorless crystals having a melting point of 165 to 166 ° C.
  • lithium aluminum hydride (4.77 g) was added to a suspension of 4.70 g of anhydrous tetrahydrofuran (2 50 ml). A solution of 7 g of anhydrous tetrahydrofuran in 250 ml was added dropwise, and the mixture was stirred at room temperature for 4 hours. Under ice-cooling, a mixture of tetrahydrofuran and a 10% aqueous sodium hydroxide solution was added dropwise to the reaction mixture. After filtering off the insolubles, the residue was washed with tetrahydrofuran, and the combined filtrate and washings were concentrated to obtain 48.1 g of a colorless liquid.
  • the obtained brown crystals were purified by silica gel column chromatography using ethyl acetate-n-hexane (1: 3) as an eluting solvent to obtain 10.6 g of pale brown crystals. Recrystallization from ⁇ -hexane gave pale brown crystals with a melting point of 96-97 ° C.
  • the extract is washed successively with water and saturated saline, and after dehydration, the solvent is removed. Distilled off. A solution of 3.03 g of the obtained pale yellow solid and 0.30 g of p-toluenesulfonic acid monohydrate in 100 ml of toluene was refluxed for 20 hours. After the reaction, the solvent was distilled off, and methanol and acetone were added to the residue, and the precipitated crystals were collected by filtration to obtain 1.79 g of colorless crystals.
  • the extract was washed successively with a saturated aqueous solution of sodium bicarbonate and a saturated saline solution and then dehydrated, and the solvent was distilled off to obtain a reddish brown liquid.
  • the obtained liquid was purified by silica gel column chromatography using ethyl acetate-n-heptane (1: 1) as an eluting solvent, and washed with diisopropyl ether to obtain 0.55 g of a colorless solid. Recrystallization from diisopropyl ether gave colorless crystals having a melting point of 146-16.5 ° C.
  • the resulting brown liquid was purified by silica gel column chromatography using ethyl acetate as a dissolving solvent to obtain 3.59 g of a colorless solid. Recrystallization from a mixture of ethyl acetate and n-hexane gave colorless crystals having a melting point of 130.5-132.5 ° C.
  • the obtained residue was purified by alumina column chromatography using methylene chloride-methanol chloride (100: 1, 20: 1) as an elution solvent, and washed with diisopropyl ether to obtain 1.88 g of colorless crystals. Recrystallization from ethyl acetate gave colorless crystals having a melting point of 193 193.5 C.
  • the obtained liquid was purified by alumina column chromatography using ethyl acetate-n-heptane (1: 1) as a solvent to obtain 0.32 g of colorless crystals. Recrystallization from isopropanol gave colorless needles mp 163-165 ° C.
  • the aqueous layer was adjusted to pH 11 with a 10% aqueous sodium hydroxide solution, and extracted from a mixed solution of 1,2-dichloroethane and methanol.
  • the extract was washed with saturated saline and then dehydrated, and the solvent was distilled off to obtain 1.74 g of a colorless liquid.
  • a part of the colorless liquid was converted into a hydrochloride by a conventional method, and recrystallized from methanol to obtain colorless crystals having a melting point of 257 to 265 ° C (decomposition).
  • a fumarate was formed by a conventional method, and recrystallized from methanol to obtain colorless crystals having a melting point of 185.5 to 186.5 ° C (decomposition).
  • the obtained liquid was dissolved in tetrahydrofuran, filtered using silica gel, and the filtrate was concentrated to obtain 0.87 g of a colorless solid. It was converted into a hydrochloride by a conventional method, and recrystallized from a mixture of methanol and ethyl acetate to obtain colorless crystals having a melting point of 144 to 158 ° C.
  • the obtained colorless liquid was solidified with ethyl acetate and washed with diethyl ether to obtain 0.80 g of colorless crystals. Recrystallization from a mixture of methylene chloride and ethyl acetate gave colorless crystals having a melting point of 173.5-176 ° C.
  • Example 201 Experimental value C, 60.79; H, 6.66; N, 21.97 According to the method of Example 200, the compound of Example 201 was obtained ( Example 201).
  • PBMCs peripheral blood mononuclear cells
  • LeucoPREP TM Becton Dickinson
  • 2 mM L-glutamine Life Technologies
  • 2.5 U / ml penicillin 1-2,5 ⁇ G / ml streptomycin Tomaishin contain a solution (Life Technologies)
  • 10% fetal calf serum-(Intergen Company) was added RPMI-1640 medium (Nissui Pharmaceutical Co., Ltd.), a cell density 1 x 10 6 cells / ml
  • the culture was performed as follows.
  • test compound was dissolved in sterile ultrapure water, dimethyl sulfoxide, or 0.1 N hydrochloric acid to a concentration of 20 M, and serially diluted with physiological saline before use. Compounds were tested in a concentration range of 10- 1 () M ⁇ l 0- 5 M .
  • a 96-well (flat bottom) MicroTest III TM tissue culture plate (Becton Dickinson) containing 180 ⁇ 1 of PBMC in the above medium was added with 1 ⁇ g / ml lipopolysaccharide (LPS) to a plate for cell culture. was added. Thirty minutes later, an additional 10 ⁇ 1 of the solution or solvent of the test compound was added to the gel, the plate was capped with a plastic lid, and incubated at 37% for 16 hours in a 5% carbon dioxide atmosphere.
  • LPS lipopolysaccharide
  • the enzymimnoassay method by the sandwich method was constructed to TNF-human IL-1? Was quantified.
  • a 96-well microtiter plate was coated with diluted anti-cytoin antibody (primary antibody) and coated. ⁇ : After washing the cells, the culture supernatant was appropriately diluted and placed in a well for incubation. Thereafter, a secondary antibody to the cytokine and a tertiary antibody to the secondary antibody were sequentially added while interposing a washing step. After the final washing, a tetramethylbenzidine solution (DAKO) was added to each gel to start a color development reaction.
  • DAKO tetramethylbenzidine solution
  • Recombinant human TNF— (INTERGEN) were used as primary, secondary, and tertiary antibodies and standards for calibration curves, respectively.
  • Monoclonal anti-human IL-1 (Cistron), polyclonal hidge anti-human IL-1 (Biogenesis), HRP-conjugated donkey anti-goat IgG (Chemicon International), Recombinant human IL-1? (R & D Systems) was used as the primary, secondary, tertiary antibody and standard for calibration curve, respectively.
  • each test compound was determined by the amount of cytokine induced by treatment with LPS and the test compound, and the amount of cytokine induced by treatment with LPS alone. Expressed as a percentage (%) divided by
  • the compound of the present invention exhibits an excellent production inhibitory effect on TNF and IL-1 and is extremely useful as an agent for preventing or treating diseases caused by these cytokines,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PCT/JP1999/004381 1998-08-12 1999-08-12 Derives de 1h-imidazopyridine WO2000009506A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP99937053A EP1104764A4 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives
EA200100230A EA200100230A1 (ru) 1998-08-12 1999-08-12 Производные 1h-имидазопиридина
HK02103246.4A HK1042295A1 (zh) 1998-08-12 1999-08-12 1h-咪唑並吡啶衍生物
HR20010144A HRP20010144A2 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives
SK194-2001A SK1942001A3 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives
BR9914306-2A BR9914306A (pt) 1998-08-12 1999-08-12 Derivados do 1h-imidazopiridina
CA002339562A CA2339562A1 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives
NZ509939A NZ509939A (en) 1998-08-12 1999-08-12 1H-imidazopyridine derivatives useful as TNF or IL-1 inhibitors
HU0103406A HUP0103406A3 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives and pharmaceutical compositions thereof
PL99346155A PL346155A1 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives
US09/744,959 US6518265B1 (en) 1998-08-12 1999-08-12 1H-imidazopyridine derivatives
AU51974/99A AU744388B2 (en) 1998-08-12 1999-08-12 1H-imidazopyridine derivatives
IL14122699A IL141226A0 (en) 1998-08-12 1999-08-12 1h-imidazopyridine derivatives
NO20010676A NO20010676L (no) 1998-08-12 2001-02-09 1H-imidazopyridinderivater
BG105271A BG105271A (bg) 1998-08-12 2001-02-19 Производни на 1h-имидазопиридин

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP24106298 1998-08-12
JP10/241062 1998-08-12
JP11216125A JP2000119271A (ja) 1998-08-12 1999-07-30 １ｈ―イミダゾピリジン誘導体
JP11/216125 1999-07-30

Publications (1)

Publication Number Publication Date
WO2000009506A1 true WO2000009506A1 (fr) 2000-02-24

Family

ID=26521247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/004381 WO2000009506A1 (fr) 1998-08-12 1999-08-12 Derives de 1h-imidazopyridine

Country Status (21)

Country Link
US (1) US6518265B1 (cs)
EP (1) EP1104764A4 (cs)
JP (1) JP2000119271A (cs)
CN (1) CN1323307A (cs)
AU (1) AU744388B2 (cs)
BG (1) BG105271A (cs)
BR (1) BR9914306A (cs)
CA (1) CA2339562A1 (cs)
CZ (1) CZ292544B6 (cs)
EA (1) EA200100230A1 (cs)
HK (1) HK1042295A1 (cs)
HR (1) HRP20010144A2 (cs)
HU (1) HUP0103406A3 (cs)
IL (1) IL141226A0 (cs)
NO (1) NO20010676L (cs)
NZ (1) NZ509939A (cs)
PL (1) PL346155A1 (cs)
SK (1) SK1942001A3 (cs)
TR (1) TR200100439T2 (cs)
TW (1) TW533209B (cs)
WO (1) WO2000009506A1 (cs)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194425B1 (en) 1997-12-11 2001-02-27 3M Innovative Properties Company Imidazonaphthyridines
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
US6245776B1 (en) 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
WO2001058900A1 (fr) * 2000-02-09 2001-08-16 Hokuriku Seiyaku Co., Ltd. Derives de 1h-imidazopyridine
WO2002016370A1 (fr) * 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. Derives de 1h-imidazopyridine
WO2002024684A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
WO2002020489A3 (en) * 2000-09-06 2002-06-06 Bristol Myers Squibb Co QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6656938B2 (en) 2000-12-08 2003-12-02 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6706728B2 (en) 1999-01-08 2004-03-16 3M Innovative Properties Company Systems and methods for treating a mucosal surface
JP2004512373A (ja) * 2000-10-31 2004-04-22 アムジエン・インコーポレーテツド 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途
WO2004035579A1 (ja) * 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6800624B2 (en) 1999-06-10 2004-10-05 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
WO2005087775A1 (ja) * 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
JP2005534636A (ja) * 2002-05-21 2005-11-17 ノバルティス アクチエンゲゼルシャフト プロテインキナーゼ依存性疾患の処置における１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体
JP2009514953A (ja) * 2005-11-04 2009-04-09 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
RU2374246C2 (ru) * 2003-06-27 2009-11-27 3М Инновейтив Пропертиз Компани N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗО-[4,5-с]-ХИНОЛИН-1-ИЛ]-1,1-ДИМЕТИЛЭТИЛ}-МЕТАНСУЛЬФОНАМИД И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ
US7678909B1 (en) * 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7683171B2 (en) 2005-02-04 2010-03-23 Bristol-Myers Squibb Company 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US8618136B2 (en) * 2002-11-06 2013-12-31 Celgene Corporation Methods for the treatment of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2014528449A (ja) * 2011-10-04 2014-10-27 ジャナス バイオセラピューティクス，インク． 新規なイミダゾールキノリン系免疫系調節剤
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2018128407A1 (ko) * 2017-01-06 2018-07-12 고려대학교 세종산학협력단 신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
KR20180081462A (ko) * 2017-01-06 2018-07-16 고려대학교 세종산학협력단 신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
IL161786A0 (en) 2001-11-29 2005-11-20 3M Innovative Properties Co Pharmaceutical formulations comprising an immune
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
NZ534566A (en) * 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
US6933294B2 (en) * 2002-04-03 2005-08-23 Bristol-Myers Squibb Company Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
WO2003103584A2 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
PT1545597E (pt) 2002-08-15 2010-12-29 3M Innovative Properties Co Composições imunoestimulantes e métodos de estimulação de uma resposta imunológica
WO2004028539A2 (en) 2002-09-26 2004-04-08 3M Innovative Properties Company 1h-imidazo dimers
EP1559716B1 (en) * 2002-11-06 2011-09-14 ASKA Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US7375180B2 (en) * 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
BRPI0408125A (pt) * 2003-03-07 2006-03-01 3M Innovative Properties Co 1-amino 1h-imidazoquinolinas
EP1608282A4 (en) 2003-03-13 2010-12-08 3M Innovative Properties Co METHODS OF DIAGNOSING SKIN LESIONS
KR20050109562A (ko) 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
CA2518445A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
JP2006522823A (ja) 2003-04-10 2006-10-05 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調節物質化合物の送達
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
BRPI0413164A (pt) * 2003-07-31 2006-10-03 3M Innovative Properties Co composições bioativas compreendendo as triazinas
US8221771B2 (en) 2003-08-05 2012-07-17 3M Innovative Properties Company Formulations containing an immune response modifier
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
CA2535338C (en) * 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
EP1660122A4 (en) * 2003-08-25 2007-10-24 3M Innovative Properties Co IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
RU2006105101A (ru) * 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co METHODS RELATING TO THE TREATMENT OF GIANCES
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
AU2004315876B2 (en) 2003-10-03 2011-05-26 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US20050096259A1 (en) * 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
ATE400573T1 (de) * 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren
US8778963B2 (en) * 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
EP1689361A4 (en) * 2003-12-02 2009-06-17 3M Innovative Properties Co THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
AR048289A1 (es) * 2003-12-04 2006-04-19 3M Innovative Properties Co Eteres de anillos imidazo sulfona sustituidos.
WO2005066172A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
WO2005066170A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
JP4991520B2 (ja) 2004-03-15 2012-08-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤製剤および方法
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005110013A2 (en) * 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
MXPA06012451A (es) * 2004-04-28 2007-01-31 3M Innovative Properties Co Composiciones y metodos para vacunacion por la mucosa.
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
HUE026644T2 (en) 2004-05-28 2016-07-28 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) * 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2571360C (en) * 2004-06-18 2014-11-25 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals
US8541438B2 (en) * 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
EP1786450A4 (en) * 2004-08-27 2009-11-11 3M Innovative Properties Co HIV IMMUNOSTIMATORY COMPOSITIONS
JP2008511683A (ja) 2004-09-02 2008-04-17 スリーエム イノベイティブ プロパティズ カンパニー ２−アミノ１ｈ−イミダゾ環構造および方法
WO2006028962A2 (en) * 2004-09-02 2006-03-16 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
CN101048404A (zh) * 2004-12-27 2007-10-03 Usv有限公司 制备4－氨基－1－异丁基－1H－咪唑[4,5－c]－喹啉(咪喹莫特)的方法
AR052447A1 (es) * 2004-12-30 2007-03-21 3M Innovative Properties Co Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
CA2592904C (en) * 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006091647A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006216799A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
CA2598695A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
JP2008531567A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
CN101175493A (zh) 2005-03-14 2008-05-07 3M创新有限公司 治疗光化性角化病的方法
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
WO2006116475A2 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
BRPI0615788A2 (pt) 2005-09-09 2011-05-24 Coley Pharm Group Inc derivados de amida e carbamato de n-{2-[4-amino (etoximetil)-1h-imidazo [4,5-c] quinolin-1-il]-1,1-dimetiletil} metanossulfonamida, composição farmacêutica destes e seus usos
JP2009515884A (ja) * 2005-11-10 2009-04-16 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性の阻害剤
EP1948185A4 (en) * 2005-11-10 2010-04-21 Glaxosmithkline Llc INHIBITORS OF AKT ACTIVITY
SI2343299T1 (sl) 2005-12-13 2016-06-30 Incyte Holdings Corporation S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b) pirimidini kot zaviralci janus kinaze
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
EP1988896A4 (en) * 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US7906506B2 (en) * 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
JP5562033B2 (ja) 2006-11-20 2014-07-30 ノバルティス アーゲー ２−メチル−２−［４−（３−メチル−２−オキソ−８−キノリン−３−イル−２，３−ジヒドロ−イミダゾ［４，５−ｃ］キノリン−１−イル）−フェニル］−プロピオニトリルの塩および結晶形態
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
PT3070090T (pt) 2007-06-13 2019-03-20 Incyte Holdings Corp Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
WO2009125808A1 (ja) * 2008-04-11 2009-10-15 第一三共株式会社 アミノシクロヘキシル誘導体
WO2009125809A1 (ja) * 2008-04-11 2009-10-15 第一三共株式会社 ピペリジン誘導体
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
CN106967070A (zh) 2009-05-22 2017-07-21 因塞特控股公司 作为jak抑制剂的化合物
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
ES2662588T3 (es) 2010-03-10 2018-04-09 Incyte Holdings Corporation Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
PT2606047T (pt) 2010-08-17 2017-04-07 3M Innovative Properties Co Composições, formulações e métodos de um composto lipidado modificador da resposta imunitária
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2011340167A1 (en) * 2010-12-06 2013-07-18 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
FI3461825T3 (fi) * 2011-09-30 2023-08-17 C&C Res Lab Uusia heterosyklisiä johdannaisia ja niiden käyttöjä
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
PE20151141A1 (es) * 2012-11-01 2015-08-06 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
HUE055894T2 (hu) 2012-11-15 2021-12-28 Incyte Holdings Corp A ruxolitinib nyújtott felszabadulású dózisformái
RU2669941C2 (ru) 2013-01-07 2018-10-17 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции и способы для лечения t-клеточной лимфомы кожи
SI3489239T1 (sl) 2013-03-06 2022-04-29 Incyte Holdings Corporation Postopki in intermediati za pripravo zaviralca JAK
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CA2920108C (en) 2013-08-07 2022-07-05 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9802957B2 (en) 2014-04-30 2017-10-31 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015171526A2 (en) * 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Tricyclic pyrazolopyridine compounds
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
EP3347047A1 (en) 2015-09-09 2018-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression vector delivery system and use thereof for inducing an immune response
KR20180053318A (ko) 2015-09-17 2018-05-21 제이알엑스 바이오테크놀로지, 인코포레이티드 피부 수화 또는 보습을 향상시키기 위한 접근법
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
EP3419655A1 (en) 2016-02-27 2019-01-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Peptide vaccines comprising self-assembling polymer nanoparticles
DK3509591T3 (da) * 2016-10-03 2021-12-20 Highlightll Pharmaceutical Hainan Co Ltd Nye jak1-selektive inhibitorer og anvendelser deraf
AU2018250226B2 (en) 2017-04-04 2025-04-24 Barinthus Biotherapeutics North America, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
PE20201342A1 (es) 2018-02-28 2020-11-25 Pfizer Variantes de il-15 y usos de las mismas
IL318069A (en) 2018-03-30 2025-02-01 Incyte Corp Using JAK inhibitors to treat hidradenitis suppurativa
WO2019226828A2 (en) 2018-05-22 2019-11-28 Avidea Technologies, Inc. Improved methods of manufacturing peptide-based vaccines
DK3797121T3 (da) 2018-05-23 2024-07-08 Pfizer Antistoffer, der er specifikke for CD3, og anvendelser deraf
SG11202010934SA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for gucy2c and uses thereof
US12053519B2 (en) 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
WO2020072681A1 (en) 2018-10-03 2020-04-09 Avidea Technologies, Inc. Aromatic ring substituted amphiphilic polymers as drug delivery systems
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
EP3955964A1 (en) 2019-04-17 2022-02-23 Avidea Technologies, Inc. Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
PE20230160A1 (es) 2019-12-17 2023-02-01 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
PH12023550139A1 (en) 2020-07-17 2024-06-24 Pfizer Therapeutic antibodies and their uses
EP4216927A1 (en) 2020-09-22 2023-08-02 Vaccitech North America, Inc. Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
US20240025899A1 (en) * 2020-10-16 2024-01-25 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
WO2022086853A1 (en) 2020-10-19 2022-04-28 Avidea Technologies, Inc. Star polymer drug conjugates
EP4263553A4 (en) * 2020-12-17 2025-03-12 Zymeworks BC Inc. IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE
JP2024506381A (ja) 2021-02-16 2024-02-13 ヴァクシテック ノース アメリカ， インコーポレイテッド 両親媒性ペプチドに基づく自己集合ナノ粒子
KR20250110948A (ko) 2022-10-25 2025-07-21 바린투스 바이오테라퓨틱스 노쓰 아메리카, 인크. 자기 조립 나노입자
AU2023367778A1 (en) 2022-10-25 2025-05-01 Barinthus Biotherapeutics North America, Inc. Combination treatment regimes for treating cancer
IL320723A (en) 2022-11-09 2025-07-01 Merck Patent Gmbh TLR7 agonists as immune stimulants to stimulate innate immunity against tumors
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145340A2 (en) * 1983-11-18 1985-06-19 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
EP0459505A1 (en) * 1990-06-01 1991-12-04 Kyowa Hakko Kogyo Co., Ltd. Imidazonaphthyridine derivatives
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH09208584A (ja) * 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
WO1998030562A1 (fr) * 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Nouveaux derives d'amide et intermediaires utilises pour leur synthese

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US346905A (en) * 1886-08-10 Heney gulick
EP0223124B1 (en) 1985-11-06 1991-06-12 Merck & Co. Inc. Substituted aminosulfonyl 6-nitrobenzoic-esters or amides, processes for their preparation and pharmaceutical compositions containing them
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3206078B2 (ja) 1992-01-28 2001-09-04 株式会社ノーリツ 燃焼機の機種セレクト装置
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0145340A2 (en) * 1983-11-18 1985-06-19 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines
US4689338A (en) * 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
EP0459505A1 (en) * 1990-06-01 1991-12-04 Kyowa Hakko Kogyo Co., Ltd. Imidazonaphthyridine derivatives
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
JPH09208584A (ja) * 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
WO1998030562A1 (fr) * 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Nouveaux derives d'amide et intermediaires utilises pour leur synthese

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. INTERFERON RES., vol. 14, 1994, pages 81 - 85, XP002928463 *
J. MED. CHEM., vol. 11, no. 1, 1968, pages 87 - 92, XP002928464 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638944B2 (en) 1997-12-11 2003-10-28 3M Innovative Properties Company Imidazonaphthyridines
US6693113B2 (en) 1997-12-11 2004-02-17 3M Innovative Properties Company 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]napthyridin-4 amine
US6194425B1 (en) 1997-12-11 2001-02-27 3M Innovative Properties Company Imidazonaphthyridines
US6514985B1 (en) 1997-12-11 2003-02-04 3M Innovative Properties Company Imidazonaphthyridines
US6624172B2 (en) 1997-12-11 2003-09-23 3M Innovative Properties Company Imidazonaphthyridines
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6245776B1 (en) 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6706728B2 (en) 1999-01-08 2004-03-16 3M Innovative Properties Company Systems and methods for treating a mucosal surface
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6800624B2 (en) 1999-06-10 2004-10-05 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US7030131B2 (en) 1999-06-10 2006-04-18 Crooks Stephen L Sulfonamide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
KR100781428B1 (ko) * 1999-06-10 2007-12-03 쓰리엠 이노베이티브 프로퍼티즈 캄파니 술폰아미드 및 술파미드 치환된 이미다조퀴놀린
US7393859B2 (en) 1999-06-10 2008-07-01 Coley Pharmaceutical Group, Inc. Amide substituted imidazoquinolines
US6891039B2 (en) 1999-10-27 2005-05-10 Novartis Ag Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use
US6608072B1 (en) 1999-10-27 2003-08-19 Novartis Ag Thiazole compounds and their pharmaceutical use
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
JP2003512467A (ja) * 1999-10-27 2003-04-02 ノバルティス アクチエンゲゼルシャフト チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6630588B2 (en) 1999-11-05 2003-10-07 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
WO2001058900A1 (fr) * 2000-02-09 2001-08-16 Hokuriku Seiyaku Co., Ltd. Derives de 1h-imidazopyridine
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
WO2002016370A1 (fr) * 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. Derives de 1h-imidazopyridine
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7173042B2 (en) 2000-09-06 2007-02-06 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
WO2002020489A3 (en) * 2000-09-06 2002-06-06 Bristol Myers Squibb Co QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
US7378430B2 (en) 2000-09-06 2008-05-27 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
US6835737B2 (en) 2000-09-06 2004-12-28 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
US7384958B2 (en) 2000-09-06 2008-06-10 Bristol-Myers Squibb Company Quinoline inhibitors of cGMP phosphodiesterase
EP1719770A3 (en) * 2000-09-21 2008-03-05 Smithkline Beecham Plc Quinoline derivatives as antibacterials
WO2002024684A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
JP2004512373A (ja) * 2000-10-31 2004-04-22 アムジエン・インコーポレーテツド 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途
US6670372B2 (en) 2000-12-08 2003-12-30 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6683088B2 (en) 2000-12-08 2004-01-27 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US7612083B2 (en) 2000-12-08 2009-11-03 Coley Pharmaceutical Group, Inc. Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6656938B2 (en) 2000-12-08 2003-12-02 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
JP2005534636A (ja) * 2002-05-21 2005-11-17 ノバルティス アクチエンゲゼルシャフト プロテインキナーゼ依存性疾患の処置における１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体
US7998972B2 (en) 2002-05-21 2011-08-16 Novartis Ag 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
WO2004035579A1 (ja) * 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US8618136B2 (en) * 2002-11-06 2013-12-31 Celgene Corporation Methods for the treatment of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
RU2374246C2 (ru) * 2003-06-27 2009-11-27 3М Инновейтив Пропертиз Компани N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗО-[4,5-с]-ХИНОЛИН-1-ИЛ]-1,1-ДИМЕТИЛЭТИЛ}-МЕТАНСУЛЬФОНАМИД И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ
US7678909B1 (en) * 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005087775A1 (ja) * 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7683171B2 (en) 2005-02-04 2010-03-23 Bristol-Myers Squibb Company 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
JP2009514953A (ja) * 2005-11-04 2009-04-09 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
JP2014528449A (ja) * 2011-10-04 2014-10-27 ジャナス バイオセラピューティクス，インク． 新規なイミダゾールキノリン系免疫系調節剤
US9873694B2 (en) 2011-10-04 2018-01-23 Janus Biotherapeutics, Inc. Imidazole quinoline-based immune system modulators
WO2018128407A1 (ko) * 2017-01-06 2018-07-12 고려대학교 세종산학협력단 신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
KR20180081462A (ko) * 2017-01-06 2018-07-16 고려대학교 세종산학협력단 신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
KR102009756B1 (ko) 2017-01-06 2019-08-12 고려대학교 세종산학협력단 신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
CN110177796A (zh) * 2017-01-06 2019-08-27 高丽大学校世宗产学协力团 新的喹啉酮衍生物和包含所述喹啉酮衍生物作为活性成分用于预防或治疗变应性疾病例如哮喘或特应性的药物组合物
US11168094B2 (en) 2017-01-06 2021-11-09 Azcuris Co., Ltd. Quinolinone derivative and pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopic dermatitis including the quinolinone derivative as active ingredient
CN110177796B (zh) * 2017-01-06 2022-04-08 阿斯克里斯有限公司 喹啉酮衍生物及其用于预防或治疗变应性疾病的药物组合物

Also Published As

Publication number Publication date
CA2339562A1 (en) 2000-02-24
HUP0103406A3 (en) 2002-11-28
CZ292544B6 (cs) 2003-10-15
EA200100230A1 (ru) 2001-10-22
IL141226A0 (en) 2002-03-10
NO20010676L (no) 2001-04-10
SK1942001A3 (en) 2001-12-03
TR200100439T2 (tr) 2001-05-21
AU744388B2 (en) 2002-02-21
HK1042295A1 (zh) 2002-08-09
NZ509939A (en) 2002-08-28
HRP20010144A2 (en) 2002-04-30
BR9914306A (pt) 2002-05-21
CN1323307A (zh) 2001-11-21
PL346155A1 (en) 2002-01-28
AU5197499A (en) 2000-03-06
HUP0103406A2 (hu) 2002-02-28
EP1104764A1 (en) 2001-06-06
US6518265B1 (en) 2003-02-11
NO20010676D0 (no) 2001-02-09
JP2000119271A (ja) 2000-04-25
TW533209B (en) 2003-05-21
EP1104764A4 (en) 2003-01-15
BG105271A (bg) 2001-11-30
CZ2001503A3 (cs) 2001-11-14

Similar Documents

Publication Publication Date Title
WO2000009506A1 (fr) Derives de 1h-imidazopyridine
US7288656B2 (en) Derivatives of N-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics
WO2001058900A1 (fr) Derives de 1h-imidazopyridine
US6294555B1 (en) 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
EP0511610B1 (en) Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments
FI82242B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-(piperidinyl)-1h-indazolderivat.
EP1357116A1 (en) 2-acylaminothiazole derivative or its salt
KR920003980B1 (ko) 축합 디아제핀온의 제조방법
US7034151B2 (en) Process for preparing pyrrolotriazine kinase inhibitors
WO2002016370A1 (fr) Derives de 1h-imidazopyridine
JP2013534229A (ja) バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体
KR20150064098A (ko) 이미다졸 유도체
CA3179059A1 (en) Collagen 1 translation inhibitors and methods of use thereof
FI98369C (fi) Menetelmä valmistaa farmaseuttisesti aktiivista 1- tai 3-difenyylimetyyli-imidatsoindolitsiinijohdannaista
WO1993008187A1 (en) Imidazopyridines and indolizines as 5-ht4 antagonists
EP0812838A1 (en) Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor
WO2002022574A1 (fr) Compose tricyclique heterocyclique, son procede de fabrication et son utilisation
WO2002057255A1 (fr) Derives du pyrrole substitues en 4 ou 5
MXPA01001378A (es) Derivados de 1h-imidazopiridina
HK1093503A1 (en) Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
HK1093503B (en) Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
WO1997017349A1 (fr) Derives heterocycliques fusionnes pentagonaux d'azepine et leur emploi pharmaceutique
JP2002161095A (ja) １ｈ−イミダゾピリジン誘導体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812056.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 141226

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2339562

Country of ref document: CA

Ref document number: 2339562

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001378

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1942001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2001-503

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2001/00439

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 51974/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 509939

Country of ref document: NZ

Ref document number: IN/PCT/2001/217/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999937053

Country of ref document: EP

Ref document number: 1020017001977

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1999 105271

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200101452

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20010144A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 200100230

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09744959

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999937053

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-503

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017001977

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 51974/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999937053

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2001-503

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017001977

Country of ref document: KR